Could a simple inhaled gas replace morphine for heart attack pain?
NCT ID NCT07445737
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial will compare methoxyflurane (Penthrox®), a painkiller gas patients inhale themselves, against standard morphine injections for chest pain during a heart attack. About 700 adults with a specific type of heart attack (STEMI) will be enrolled in pre-hospital settings. The goal is to see if methoxyflurane is at least as good as morphine at relieving pain within 30 minutes, with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Methoxyflurane (Penthrox®) inhaled gas
- What this could lead to
- If it works, this could offer a faster, easier-to-use pain relief option for heart attack patients without needing an IV line.
- What could go wrong
- This is a non-inferiority trial, so it may only show methoxyflurane is not worse than morphine, not necessarily better. It has not started recruiting yet, and results may not apply to all heart attack patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 700 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient age ≥ 18 years * Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI) : Chest pain \< 12 hours with moderate to severe pain (VAS \> 6/10) or STEMI on ECG according to 2017 ESC guidelines Exclusion Criteria: * Previous analgesic treatment for this episode of chest pain * Hypersensitivity to morphine, methoxyflurane, any fluorinated anesthetic or any of the excipients listed in SmPC, * Decompensated respiratory failure (in the absence of artificial ventilation), * Severe hepatocellular insufficiency (with encephalopathy), * Acute head trauma and intracranial hypertension in the absence of controlled ventilation, * Uncontrolled epilepsy, * Treatment with buprenorphine, nalbuphine and pentazocine, naltrexone, nalmefene or sodium oxybate, * Breastfeeding, in case of initiation or continuation after birth of a long-term treatment. * Known malignant hyperthermia or genetic predisposition of the patient. * History of serious adverse effects of the patient or his family after administration of inhaled anesthetics. * History of signs of liver damage after use of methoxyflurane or after anesthesia with a halogenated hydrocarbon. * Clinically significant renal impairment. * Known renal failure with creatinine clearance below 30 ml/min or undergoing extracorporeal renal replacement therapy. * Altered level of consciousness due to any cause, including head trauma, drug or alcohol use. * Clinical evidence of cardiovascular instability (PAS \<90 mm Hg). * Clinical evidence of respiratory depression. * Incapacity to self-assess pain intensity * Incapacity to methoxyflurane self-administration * Known pregnancy, breastfeeding, minors or incapacity (curatorship or guardianship) * Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants * Absence of a Social Security
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stemi - ST elevation myocardial infarction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Avicenne
Bobigny, 93000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive chest pain registry reveals gaps between guidelines and real-world care in china
- Simple arm cuff before angioplasty may boost heart attack recovery
- Suction device may improve outcomes in heart attack patients with large clots
- AI blood test could spot heart attacks faster
- Heart attack patients may benefit from Clot-Busting drug before delayed procedure
- Heart attack patients to receive injectable gel that may limit damage